An aberrant DNA methylation signature for predicting hepatocellular carcinoma.

Zhang, Renhua; Li, Yafei; Yu, Hao; Liu, Lin; Zhu, Changhao; Zuo, Shi; Chen, Zili

Zhang, Renhua; Li, Yafei; Yu, Hao; Liu, Lin; Zhu, Changhao; Zuo, Shi; Chen, Zili.

Afiliação

Zhang R; Information Communication Division, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, China.
Li Y; Information Communication Division, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, China.
Yu H; Information Communication Division, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, China.
Liu L; Information Communication Division, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, China.
Zhu C; Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Zuo S; Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Chen Z; Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Ann Transl Med ; 8(24): 1667, 2020 Dec.

Article em En | MEDLINE | ID: mdl-33490179

Palavras-chave

Hepatocellular carcinoma (HCC); methylated sites; overall survival (OS); prognosis; signature

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Transl Med Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China País de publicação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google